ZA202100919B - Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof - Google Patents

Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof

Info

Publication number
ZA202100919B
ZA202100919B ZA2021/00919A ZA202100919A ZA202100919B ZA 202100919 B ZA202100919 B ZA 202100919B ZA 2021/00919 A ZA2021/00919 A ZA 2021/00919A ZA 202100919 A ZA202100919 A ZA 202100919A ZA 202100919 B ZA202100919 B ZA 202100919B
Authority
ZA
South Africa
Prior art keywords
epsilon
alpha
fcer1a
antibodies
bind
Prior art date
Application number
ZA2021/00919A
Other languages
English (en)
Inventor
Jamie M Orengo
Andre Limnander
Jee H Kim
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of ZA202100919B publication Critical patent/ZA202100919B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA2021/00919A 2018-08-23 2021-02-10 Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof ZA202100919B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862721921P 2018-08-23 2018-08-23
PCT/US2019/047601 WO2020041537A1 (en) 2018-08-23 2019-08-22 Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof

Publications (1)

Publication Number Publication Date
ZA202100919B true ZA202100919B (en) 2025-10-29

Family

ID=67876086

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2021/00919A ZA202100919B (en) 2018-08-23 2021-02-10 Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof

Country Status (18)

Country Link
US (2) US11578127B2 (cg-RX-API-DMAC7.html)
EP (1) EP3840841A1 (cg-RX-API-DMAC7.html)
JP (2) JP7402223B2 (cg-RX-API-DMAC7.html)
KR (1) KR102977145B1 (cg-RX-API-DMAC7.html)
CN (1) CN112888482B (cg-RX-API-DMAC7.html)
AU (1) AU2019325565B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021003023A2 (cg-RX-API-DMAC7.html)
CA (1) CA3109513A1 (cg-RX-API-DMAC7.html)
CL (2) CL2021000437A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021003608A2 (cg-RX-API-DMAC7.html)
EA (1) EA202190601A1 (cg-RX-API-DMAC7.html)
IL (1) IL280745B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021002165A (cg-RX-API-DMAC7.html)
MY (1) MY204368A (cg-RX-API-DMAC7.html)
PH (1) PH12021550322A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101608XA (cg-RX-API-DMAC7.html)
WO (1) WO2020041537A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202100919B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021002165A (es) 2018-08-23 2021-07-16 Regeneron Pharma Anticuerpos anti-fc épsilon-r1 alfa (fcer1a), moléculas de unión a antígeno biespecíficas que se unen a fcer1a y cd3 y usos de éstos.
US20230056380A1 (en) * 2020-01-31 2023-02-23 Randy Leiman Allen Methods and kit for detection of analytes
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
NZ553118A (en) * 2004-09-02 2009-12-24 Genentech Inc Anti-FC-gamma RIIB receptor antibody and uses therefor
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
WO2012142286A1 (en) * 2011-04-12 2012-10-18 University Of Cincinnati Methods for suppressing allergic reactions
WO2012169741A2 (ko) 2011-06-07 2012-12-13 (주)네오팜 FcεRI 특이적 인간 항체 및 이를 포함하는 알레르기 질환 치료 또는 진단용 조성물
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
EP2837637A1 (en) 2013-08-16 2015-02-18 SuppreMol GmbH Novel anti-FcyRIIB IgG-type antibody
CN104293738A (zh) 2013-09-11 2015-01-21 李莉 一种抗人FcεRⅠα亚基单克隆抗体及其应用
EP2982693A1 (en) * 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
EA035269B1 (ru) 2014-08-13 2020-05-22 Зуппремоль Гмбх АНТИТЕЛО, НАПРАВЛЕННОЕ НА Fc-ГАММА-РЕЦЕПТОР IIB И Fc-ЭПСИЛОН-РЕЦЕПТОР
CN104800164B (zh) 2015-04-13 2017-11-07 上海市第一人民医院 一种雷公藤免疫纳米粒及用途
MY195059A (en) 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
EP3443006B1 (en) * 2016-04-13 2023-08-02 Sanofi Trispecific and/or trivalent binding proteins
KR102531251B1 (ko) * 2016-09-23 2023-05-15 리제너론 파아마슈티컬스, 인크. 이특이적 항-muc16-cd3 항체 및 항-muc16 약물 접합체
MX2021002165A (es) 2018-08-23 2021-07-16 Regeneron Pharma Anticuerpos anti-fc épsilon-r1 alfa (fcer1a), moléculas de unión a antígeno biespecíficas que se unen a fcer1a y cd3 y usos de éstos.

Also Published As

Publication number Publication date
JP2023171909A (ja) 2023-12-05
EA202190601A1 (ru) 2021-07-14
IL280745B2 (en) 2026-06-01
KR102977145B1 (ko) 2026-06-12
JP7402223B2 (ja) 2023-12-20
US20230331845A1 (en) 2023-10-19
EP3840841A1 (en) 2021-06-30
IL280745A (en) 2021-04-29
PH12021550322A1 (en) 2021-10-04
US12441797B2 (en) 2025-10-14
US11578127B2 (en) 2023-02-14
WO2020041537A1 (en) 2020-02-27
KR20210049863A (ko) 2021-05-06
WO2020041537A8 (en) 2020-09-10
JP7541167B2 (ja) 2024-08-27
MY204368A (en) 2024-08-26
CA3109513A1 (en) 2020-02-27
BR112021003023A2 (pt) 2021-05-11
CL2021000437A1 (es) 2021-09-03
CL2023000442A1 (es) 2023-11-24
CO2021003608A2 (es) 2021-04-30
NZ772900A (en) 2025-05-02
US20200062844A1 (en) 2020-02-27
SG11202101608XA (en) 2021-03-30
AU2019325565A1 (en) 2021-03-11
AU2019325565B2 (en) 2025-09-04
CN112888482B (zh) 2024-06-25
IL280745B1 (en) 2026-02-01
CN112888482A (zh) 2021-06-01
MX2021002165A (es) 2021-07-16
JP2021533806A (ja) 2021-12-09

Similar Documents

Publication Publication Date Title
MX2025005515A (es) Anticuerpos anti-bcma x anti-cd3 biespecificos y usos de estos
MY208537A (en) Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof
MX2020013804A (es) Anticuerpos anti-psma x anti-cd28 biespecíficos y usos de estos.
SA522431672B1 (ar) Cd3 أجسام مضادة للارتباط بـ
JOP20210071A1 (ar) أجسام مضادة مثبّتة trem2
MX2024005027A (es) Anticuerpos de union a cd3.
MX2021007497A (es) Anticuerpos biespecificos anti-cd28 x anti-cd22 y usos de estos.
PH12021550322A1 (en) Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof
PH12018550179A1 (en) Anti-pd-1 antibodies, method for producing same and method for using same
JOP20190248A1 (ar) بروتينات ربط مولد ضد trem2 واستخداماته
EA201990781A9 (ru) Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение
BR112022009317A2 (pt) Anticorpos de cd73 biparatópicos
JOP20190116A1 (ar) الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
PH12020551153A1 (en) Antibodies specific for cd70 and their uses
MX2024005841A (es) Moleculas de union a cd32b x cd79b para usarse como medicamentos para el tratamiento de enfermedades o trastornos inflamatorios y para reducir las respuestas inmunitarias.
MY209615A (en) Extracellular domain of alpha subunit of ige fc receptor, pharmaceutical composition comprising same and method for producing same
MX2022009815A (es) Moleculas de union biespecificas.
MX2023012300A (es) Anticuerpos humanos contra artemina y metodos de uso de estos.
EA202190314A1 (ru) Биспецифические анти-bcma x анти-cd3 антитела и способы их применения
MX2025010217A (es) Anticuerpos multiespecificos anti-cd3 y metodos de uso
MX2025010882A (es) Anticuerpos anti-gpvi y fragmentos funcionales de los mismos
TH2101000210A (th) ไบสเปซิฟิกแอนติ-BCMA x แอนติ-CD3 แอนติบอดี และการใช้แอนติบอดีดังกล่าว
EA202191677A1 (ru) Биспецифичные антитела анти-muc16 x анти-cd28 и варианты их применения
PH12022553391A1 (en) Humanized anti-emap ii therapeutic antibodies
TH1901000154A (th) แอนติบอดีต้าน pd-1, วิธีการผลิตและวิธีการใช้ของสิ่งดังกล่าว